Versant Ventures has made key appointments in Canada, the US and Switzerland in advance of the launch of its sixth fund, which is expected to reach $400 million. The San Francisco-based venture fund has $2.3 billion under management and has been increasingly active in Canada, most recently teaming with Bayer AG to invest $300 million in the Toronto-based life sciences start-up, Blue Rock Therapeutics. The Canadian venture partners are Dr Mary Haak-Frendscho (Toronto), CEO of Blueline Bioscience located at the MaRS Disovery District, and Lloyd Segal (Montreal) who will lead a new Canada-based series ‘A’ oncology start-up backed by Versant.
Trending by Topic
Research Money News
Conference Proceedings now available
The proceedings from the 2017 RE$EARCH MONEY Conference are now available. Download them here.Read More
R$ Welcomes New Team Member
We’re delighted to welcome Mark Lowey as senior correspondent for Research Money.Read More
RE$EARCH MONEY welcomes its readers to submit articles of either 650 or 1,000 words for its popular Opinion Leader page, on topics of interest to the research and innovation community. We also welcome Letters to the Editor and other feedback. If you would like to submit an article or if your organization has news or events that it would like to appear in RE$EARCH MONEY please contact Mark Henderson, Managing Editor, for further information.
- National Research Council
- Natural Sciences and Engineering Research Council
- Canada Foundation for Innovation
- Univ of Toronto
- Univ of British Columbia
- Canadian Institutes of Health Research
- Technology Partnerships Canada
- McGill Univ
- Univ of Alberta
- Univ of Waterloo
Research Money on Twitter
- Loading tweets...